{
  "items": "27",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "CITIUS ONCOLOGY, INC. SEC 10-K Report",
      "url": "https://www.tradingview.com/news/tradingview:4ac62af70f401:0-citius-oncology-inc-sec-10-k-report/",
      "time_published": "20251224T041001",
      "authors": [
        "NULL"
      ],
      "summary": "Citius Oncology, Inc. (CTOR) has released its annual 10-K report for the fiscal year ending September 30, 2025, detailing no revenues, a net loss of $24.76 million, and the FDA approval and upcoming commercialization of its lead product, LYMPHIR. The company is facing significant financial risks, including a going concern doubt from its auditors, and is actively seeking additional capital and exploring strategic alternatives to support operations and commercialization efforts beyond March 2026.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.931303"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.918185"
        },
        {
          "topic": "finance",
          "relevance_score": "0.743039"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.610475"
        }
      ],
      "overall_sentiment_score": 0.072399,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.140544",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.647114",
          "ticker_sentiment_score": "0.101799",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.624139",
          "ticker_sentiment_score": "0.104021",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCK",
          "relevance_score": "0.609573",
          "ticker_sentiment_score": "0.122771",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "New cancer drug LYMPHIR reaches U.S. patients after FDA approval",
      "url": "https://www.stocktitan.net/news/CTOR/citius-pharmaceuticals-inc-reports-fiscal-year-2025-financial-88r1ggpfk9ct.html",
      "time_published": "20251224T040931",
      "authors": [
        "NULL"
      ],
      "summary": "Citius Pharmaceuticals (CTOR) announced its subsidiary Citius Oncology launched LYMPHIR (denileukin diftitox-cxdl) in the U.S. in December 2025 following FDA approval for adult patients with relapsed or refractory Stage I-III CTCL. The company secured distribution agreements and access in 19 international markets, along with an NCCN Category 2A recommendation and a permanent HCPCS J-code. While recording a net loss of $39.7 million for fiscal year 2025, Citius raised approximately $61 million in gross proceeds from financings.",
      "banner_image": "https://mma.prnewswire.com/media/1593817/Citius_32.jpg",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.604576"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.936635"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.905013"
        }
      ],
      "overall_sentiment_score": 0.204743,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.255206",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.551726",
          "ticker_sentiment_score": "0.130836",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR",
      "url": "https://markets.financialcontent.com/stocks/article/marketminute-2025-12-23-citius-oncology-transitions-to-commercial-stage-analyzing-the-10-k-filing-and-the-2026-outlook-for-lymphir",
      "time_published": "20251223T171900",
      "authors": [
        "MarketMinute"
      ],
      "summary": "Citius Oncology, Inc. (Nasdaq: CTOR) has transitioned to a commercial-stage company following its 10-K filing for the fiscal year ended September 30, 2025, and the December launch of its immunotherapy LYMPHIR. The company navigated significant financial challenges and strategic delays by securing a permanent J-code (J9161) and distribution agreements, setting the stage for a high-stakes 2026. The 2026 outlook involves rapid LYMPHIR sales adoption in the CTCL market and potential expansion into Peripheral T-Cell Lymphoma (PTCL), with analysts projecting ambitious revenue targets.",
      "banner_image": "https://marketminute.ghost.io/content/images/size/w1200/2025/12/43f5f670-3e8a-442a-a1bf-f9a2d74240f1.png",
      "source": "FinancialContent",
      "category_within_source": "General",
      "source_domain": "FinancialContent",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933172"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.833571"
        }
      ],
      "overall_sentiment_score": 0.178146,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.965998",
          "ticker_sentiment_score": "0.425328",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.610001",
          "ticker_sentiment_score": "0.115243",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.627619",
          "ticker_sentiment_score": "0.117684",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCK",
          "relevance_score": "0.584465",
          "ticker_sentiment_score": "0.102368",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology raises $18M through direct offering",
      "url": "https://www.msn.com/en-us/money/topstocks/citius-oncology-raises-18m-through-direct-offering/ar-AA1S7x8C",
      "time_published": "20251223T101001",
      "authors": [],
      "summary": "Citius Oncology has successfully raised $18 million through a direct offering. This funding round demonstrates investor confidence in the company's oncology pipeline and future prospects. The capital will likely be used to advance its clinical programs and research efforts in the oncology sector.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.940583"
        },
        {
          "topic": "finance",
          "relevance_score": "0.709252"
        }
      ],
      "overall_sentiment_score": 0.449904,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.402287",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology closes $18 million in offerings to support LYMPHIR launch",
      "url": "https://ng.investing.com/news/company-news/citius-oncology-closes-18-million-in-offerings-to-support-lymphir-launch-93CH-2248838",
      "time_published": "20251211T120946",
      "authors": [
        "Investing.com"
      ],
      "summary": "Citius Oncology (NASDAQ:CTOR) secured approximately $18 million through concurrent financing transactions to fund the commercial launch of LYMPHIR, its FDA-approved cancer treatment for cutaneous T-cell lymphoma (CTCL). The company completed a registered direct offering and a private placement, issuing common stock and warrants at $1.09 per share, with H.C. Wainwright & Co. acting as placement agent. These funds will support LYMPHIR's market entry in the U.S. and its expanded international distribution to 19 markets.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.918394"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.826151"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.701009"
        }
      ],
      "overall_sentiment_score": 0.455741,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.470750",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology Raises $18M Through Direct Offering",
      "url": "https://www.tipranks.com/news/company-announcements/citius-oncology-raises-18m-through-direct-offering",
      "time_published": "20251210T230958",
      "authors": [
        "Citius Oncology Raises $18M Through Direct Offering - TipRanks.com Stocks Top Analyst Stocks Popular Top Smart Score Stocks Popular AI Analyst Top Stocks New Top Insiders Stocks Market Movers TipRanks 50 Index AI Stocks Largest Companies by Market Cap ETFs Top ETFs by Upside Top ETFs by Smart Score Top Gainers/ Losers/ Active ETFs Crypto Bitcoin Popular Ethereum Commodities Gold Options Unusual Options Activity Popular Currency EUR/USD Ideas Plans Research Tools Trending Stocks Compare Stocks Compare ETFs Trump Dashboard New Daily Feeds Daily Analyst Ratings Daily Insider Trading Tracker Calendars Earnings Calendar Dividend Calendar Economic Calendar IPO Calendar Stock Splits Stock Buybacks FDA Calendar Market Holidays Calculators Dividend Calculator Dividend Yield Calculator Options Profit Calculator Economic Indicators Inflation Rate Unemployment Rate Class Actions Tools Plans Stock Screener ETF Screener Popular Penny Stock Screener Technical Analysis Screener Screeners Plans Dividend Center Best Dividend Stocks Popular Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison New Dividend Calculator Dividend Returns Comparison Dividend Calendar Dividends Plans My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors Experts Plans Portfolio Plans Trending News More News > News Plans Private Companies Plans Enterprise Solutions Plans Education Personal Finance How To Use TipRanks TipRanks Labs Glossary FAQs About Us About TipRanks Contact Us Reviews Mobile APP Working with TipRanks Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire Follow Us More Plans Plans & Pricing Plans TOOLS Portfolio Watchlist Top Insiders Stocks Popular Top Stocks Popular Market Movers Compare stocks Compare ETFs Notification Center News Screeners Stock Screener ETF Screener Popular Penny Stock Screener Technical Analysis Screener Ideas Top Analyst Stocks Popular Top Smart Score Stocks Popular AI Analyst Top Stocks New Top Insiders Stocks Research Tools Compare Stocks Compare ETFs Trending Stocks Daily Analyst Ratings Daily Insiders Trades Dividend Stocks ETF Center Top Gainers/losers/active ETFs Trump Dashboard New Calculators Dividend Calculator Options Profit Calculator Dollar Cost Averaging Compound Interest Calculator Mortgage Calculator Auto Loan Calculator Student Loan Calculator 401k Retirement Calculator Calendars Earnings Calendar Dividend Calendar Economic Calendar IPO Calendar Stock Splits Stock Buybacks FDA Calendar Market Holidays Dividends Dividend Center Best Dividend Stocks Popular Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison New Dividend Calculator Dividend Returns Comparison Dividend Calendar Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors Market Movers Top Gainers Top Losers Most Active Premarket After-hours Private Companies Personal Finance Personal Finance Center Mortgages Loans Investing & Retirement Spending & Savings Real Estate Top Online Brokers Enterprise Solutions Plans & Pricing More Education How To Use TipRanks TipRanks Labs Glossary FAQs About Us About TipRanks Contact Us Careers Reviews Mobile APP Working with TipRanks Enterprise Solutions Top Online Brokers Become an Affiliate TipRanks News Wire Follow Us STOCKS SPY QQQ AAPL NVDA TSLA AMZN BABA Log Out Advertisement Advertisement Citius Oncology Raises $18M Through Direct Offering TipRanks Auto-Generated Newsdesk A+ A- Story Highlights Citius Oncology raised $18 million through a securities purchase agreement. Proceeds will support LYMPHIR\u2019s launch and general corporate purposes. Looking for the best stocks to buy? Follow the recommendations of top-performing analysts. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Citius Oncology ( (CTOR) ) has provided an announcement. On December 8",
        "2025",
        "Citius Oncology entered into a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement",
        "raising approximately $18 million. The proceeds will support the commercial launch of LYMPHIR and general corporate purposes. The offering closed on December 10",
        "2025",
        "with H.C. Wainwright & Co. acting as the exclusive placement agent. The company also amended existing warrants to reduce exercise prices and adjusted the maturity of a promissory note with Citius Pharmaceuticals. The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock",
        "see the CTOR Stock Forecast page . Spark\u2019s Take on CTOR Stock According to Spark",
        "TipRanks\u2019 AI Analyst",
        "CTOR is a Neutral. Citius Oncology\u2019s stock score reflects significant financial challenges and bearish technical indicators",
        "offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum",
        "while the valuation presents a more optimistic perspective due to the low P/E ratio. To see Spark\u2019s full report on CTOR stock",
        "click here . More about Citius Oncology Citius Oncology",
        "Inc. is a platform focused on developing and commercializing novel targeted oncology therapies. The company recently launched LYMPHIR",
        "a cancer immunotherapy approved by the FDA for treating adults with relapsed or refractory Stage I\u2013III cutaneous T-cell lymphoma (CTCL). The initial market for LYMPHIR is estimated to exceed $400 million and is underserved by existing therapies. Average Trading Volume: 371",
        "349 Technical Sentiment Signal: Sell Current Market Cap: $91.03M See more data about CTOR stock on TipRanks\u2019 Stock Analysis page . Trending Articles: The Key to the Warner Bros. Discovery (NASDAQ:WBD) Buy May Be Cable Channels Ford Stock (NYSE:F) Jumps as Dealerships Sue SambaNova Systems One Step Closer to Purchase: Intel Stock (NASDAQ:INTC) Slips Disclaimer & Disclosure Report an Issue Continue Reading Looking for  investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks! Get real-time notifications on news & analysis",
        "curated for your stock watchlist. Download the TipRanks app today! Get the App 1 Latest News Feed More Market News > More Articles More News > Stock Comparison Quantum Computing AI Cryptocurrency Bitcoin Stocks Dividend Value Biotech Oil Chinese Chat GPT Banks Airline Beer & Beverages Energy Investment Ideas Analyst Top Stocks Smart Score Stocks Stock Screener Top Wall Street Analysts Insiders' Hot Stocks Top Penny Stocks Unusual Options Activity Top ETFs by Upside Potential Advertisement TipRanks is a comprehensive research tool that helps investors make better",
        "data-driven investment decisions. Find Us on Newsletter Subscription Enter your email to receive our newsletter SIGN UP I agree to TipRanks Terms of use and Privacy Policy Terms of Use Privacy Policy FAQ Education How To Use TipRanks TipRanks Labs Glossary FAQs About us About TipRanks Contact Us Reviews Working With TipRanks Enterprise Solutions Top Online Brokers Become an Affiliate TipRanks News Wire Plans Plans & Pricing API for Institutions Real Estate Opportunities Arrived Find Us on Terms of Use Privacy Policy FAQ Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically",
        "backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed",
        "results may have under- or over-compensated for the impact",
        "if any",
        "of certain market factors",
        "such as lack of liquidity",
        "and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further",
        "backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and",
        "except where otherwise indicated",
        "are presented gross-of fees and do not include the effect of backtested transaction costs",
        "management fees",
        "performance fees or expenses",
        "if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation."
      ],
      "summary": "Citius Oncology (CTOR) recently raised approximately $18 million through a direct offering and concurrent private placement, with proceeds earmarked for the commercial launch of its cancer immunotherapy, LYMPHIR, and general corporate purposes. The offering closed on December 10, 2025, and included amendments to existing warrants and a promissory note. While a recent analyst rating suggests a \"Buy\" with a $6.00 price target, Spark, TipRanks' AI Analyst, views CTOR as \"Neutral\" due to financial challenges and bearish technical indicators, despite potential undervaluation suggested by a low P/E ratio.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1096459574-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.810903"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.911606"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.708588"
        }
      ],
      "overall_sentiment_score": -0.101523,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.213730",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "INTC",
          "relevance_score": "0.540586",
          "ticker_sentiment_score": "0.046585",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology stock tumbles after $18M capital raise",
      "url": "https://www.investing.com/news/stock-market-news/citius-oncology-stock-tumbles-after-18m-capital-raise-93CH-4398724",
      "time_published": "20251209T085600",
      "authors": [
        "Investing.com"
      ],
      "summary": "Citius Oncology Inc (NASDAQ:CTOR) stock fell 13.8% after announcing an $18 million capital raise through direct and private placement offerings. The funds, raised at $1.09 per share with accompanying warrants, will support the commercial launch of LYMPHIR\u2122 for cutaneous T-cell lymphoma (CTCL), as well as working capital and general corporate purposes. The stock decline is attributed to potential dilution for existing shareholders, a common reaction to equity offerings.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXMPEC0409P_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.931605"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.809446"
        },
        {
          "topic": "finance",
          "relevance_score": "0.731329"
        }
      ],
      "overall_sentiment_score": 0.016671,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.306924",
          "ticker_sentiment_score": "0.039715",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Expands LYMPHIR\u2122 Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim",
      "url": "https://www.cbs42.com/business/press-releases/cision/20251204NY38488/citius-oncology-expands-lymphir-distribution-to-turkey-and-middle-east-countries-through-exclusive-agreement-with-er-kim",
      "time_published": "20251205T071024",
      "authors": [
        "NULL"
      ],
      "summary": "Citius Oncology has signed an exclusive distribution agreement with Er-Kim to expand the distribution of LYMPHIR\u2122 (denileukin diftitox-cxdl) to Turkey and several Middle Eastern countries. This partnership aims to provide patients with cutaneous T-cell lymphoma access to the FDA-approved therapy and increases LYMPHIR's international availability to 19 markets outside the U.S. Er-Kim will handle sales, marketing, and reimbursement, further solidifying Citius Oncology's global expansion strategy.",
      "banner_image": "https://mma.prnewswire.com/media/2588198/Citius_Oncology_Logo.jpg?p=publish",
      "source": "CBS 42",
      "category_within_source": "General",
      "source_domain": "CBS 42",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.469313,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.470456",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology Expands LYMPHIR\u2122 Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim",
      "url": "https://www.prnewswire.com/news-releases/citius-oncology-expands-lymphir-distribution-to-turkey-and-middle-east-countries-through-exclusive-agreement-with-er-kim-302632064.html",
      "time_published": "20251205T040135",
      "authors": [
        "NULL"
      ],
      "summary": "Citius Oncology has signed an exclusive distribution agreement with Er-Kim to expand the distribution of LYMPHIR\u2122 to Turkey and several Middle Eastern countries. This partnership aims to provide access to LYMPHIR, a targeted immune therapy for cutaneous T-cell lymphoma, to patients in 19 markets outside the U.S. through Named Patient Programs. Er-Kim will manage sales, marketing, and reimbursement activities, leveraging its expertise in these complex international markets.",
      "banner_image": "https://mma.prnewswire.com/media/2833192/LYMPHIR_packaging.jpg?w=300",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.645759"
        }
      ],
      "overall_sentiment_score": 0.635002,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.621934",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CTOR - Citius Oncology, Inc. Latest Stock News & Market Updates",
      "url": "https://www.stocktitan.net/news/CTOR/page-3.html",
      "time_published": "20251203T040135",
      "authors": [
        "NULL"
      ],
      "summary": "This page provides the latest news and updates for Citius Oncology, Inc. (CTOR), focusing on its flagship treatment LYMPHIR\u00ae for cutaneous T-cell lymphoma. It covers financial results, strategic initiatives like engaging Jefferies to explore alternatives, regulatory milestones such as a permanent J-code for LYMPHIR, and clinical developments including trial results for LYMPHIR in combination therapies. The company is preparing for LYMPHIR's commercial launch in the first half of 2025 and is exploring partnerships for further growth.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.824567"
        },
        {
          "topic": "finance",
          "relevance_score": "0.631308"
        }
      ],
      "overall_sentiment_score": -0.219838,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.205509",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL",
      "url": "https://www.tradingview.com/news/tradingview:ae97fe9ddc018:0-citius-oncology-inc-announces-u-s-launch-of-lymphir-for-ctcl/",
      "time_published": "20251202T040135",
      "authors": [
        "NULL"
      ],
      "summary": "Citius Oncology, Inc. has announced the U.S. commercial launch of LYMPHIR, a new cancer immunotherapy for relapsed or refractory Stage I-III CTCL. LYMPHIR, approved by the FDA, demonstrated a 36.2% Objective Response Rate in a pivotal study and addresses significant quality of life issues. The company estimates a U.S. market of over $400 million, with potential for international expansion.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933648"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.642297"
        }
      ],
      "overall_sentiment_score": 0.820005,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.812944",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology Announces U.S. Commercial Launch of LYMPHIR\u2122, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)",
      "url": "https://finance.yahoo.com/news/citius-oncology-announces-u-commercial-170000760.html",
      "time_published": "20251201T160918",
      "authors": [],
      "summary": "Citius Oncology has officially launched LYMPHIR\u2122 (denileukin diftitox-cxdl) in the U.S., a new FDA-approved immunotherapy for adults with relapsed or refractory Stage I\u2013III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The company anticipates LYMPHIR will address a significant unmet medical need in a U.S. market valued over $400 million, offering rapid skin relief and a new treatment option for a disease with limited therapies. LYMPHIR is now available nationwide through specialty distributors, supported by medical education and patient assistance programs, and has been included in NCCN Guidelines\u00ae with a Category 2A recommendation.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/Y7yRYhExsI_UDfOpi5jbzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExODtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-02/fdc494d0-7160-11eb-bdff-bdf03c7194b2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934279"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.612150"
        }
      ],
      "overall_sentiment_score": 0.479418,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.465637",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences - The Malaysian Reserve",
      "url": "https://themalaysianreserve.com/2025/10/18/citius-pharmaceuticals-and-citius-oncology-to-participate-in-upcoming-october-2025-conferences/",
      "time_published": "20251018T193243",
      "authors": [],
      "summary": "Citius Pharmaceuticals and Citius Oncology are set to participate in several conferences throughout October 2025. These events will provide platforms for the companies to discuss their advancements and strategies in the pharmaceutical and oncology sectors. This engagement highlights their commitment to showcasing their progress and connecting with industry stakeholders.",
      "banner_image": null,
      "source": "The Malaysian Reserve",
      "category_within_source": "General",
      "source_domain": "The Malaysian Reserve",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.049113,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.317562",
          "ticker_sentiment_score": "0.016731",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Fourth Quarter 2025 Launch of LYMPHIR - MarketScreener",
      "url": "https://www.marketscreener.com/news/citius-oncology-signs-exclusive-commercialization-agreement-with-eversana-to-support-planned-fourth-ce7d5adcdd8af525",
      "time_published": "20251016T153846",
      "authors": [
        "S&P Capital IQ"
      ],
      "summary": "Citius Oncology has signed an exclusive commercialization agreement with EVERSANA for its FDA-approved therapy LYMPHIR (denileukin), aiming for a fourth-quarter 2025 U.S. launch. EVERSANA will provide comprehensive pre- and post-launch operational services, expanding its existing role in Citius Oncology's pre-commercial strategy. This partnership is crucial for the successful market entry of LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL).",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930713"
        },
        {
          "topic": "finance",
          "relevance_score": "0.731223"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.532717"
        }
      ],
      "overall_sentiment_score": 0.038717,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.304561",
          "ticker_sentiment_score": "0.007699",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4 - MarketScreener",
      "url": "https://www.marketscreener.com/news/citius-oncology-says-commercialization-deal-signed-with-eversana-for-planned-launch-of-lymphir-in-q4-ce7d5adcda8bf325",
      "time_published": "20251016T133712",
      "authors": [
        "MT Newswires"
      ],
      "summary": "Citius Oncology has signed a commercialization deal with Eversana for the planned launch of its drug Lymphir in Q4 2025. Lymphir is an engineered IL-2 diphtheria toxin fusion protein intended for the treatment of persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The article also provides recent financial news and analyst consensus for Citius Oncology, Inc.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.707693"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.405255"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.326653"
        }
      ],
      "overall_sentiment_score": 0.015173,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.308466",
          "ticker_sentiment_score": "0.044035",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology signs exclusive commercialization agreement with Eversana to support planned Q4 2025 launch of Lymphir - MarketScreener",
      "url": "https://www.marketscreener.com/news/citius-oncology-signs-exclusive-commercialization-agreement-with-eversana-to-support-planned-q4-202-ce7d5adcdb8cf221",
      "time_published": "20251016T125016",
      "authors": [
        "Reuters"
      ],
      "summary": "Citius Oncology has signed an exclusive commercialization agreement with Eversana to support the planned Q4 2025 launch of Lymphir. This strategic partnership aims to enhance access and distribution for Lymphir, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). The agreement is a significant step for Citius Oncology as it prepares to bring its lead product candidate to market.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928132"
        },
        {
          "topic": "finance",
          "relevance_score": "0.736452"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.539687"
        }
      ],
      "overall_sentiment_score": 0.029588,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.315579",
          "ticker_sentiment_score": "0.046671",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR - TradingView",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_TUA1XFCBY:0-citius-oncology-signs-exclusive-commercialization-agreement-with-eversana-to-support-planned-q4-2025-launch-of-lymphir/",
      "time_published": "20251016T124924",
      "authors": [
        "Refinitiv"
      ],
      "summary": "Citius Oncology Inc. has signed an exclusive commercialization agreement with EVERSANA to support the planned Q4 2025 launch of their product, LYMPHIR\u2122. The company intends to commercially launch LYMPHIR\u2122 in the United States during the fourth quarter of 2025.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.901670"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.747454"
        }
      ],
      "overall_sentiment_score": 0.001394,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.302193",
          "ticker_sentiment_score": "0.044578",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR\u2122 - Yahoo Finance",
      "url": "https://finance.yahoo.com/news/citius-oncology-signs-exclusive-commercialization-124700175.html",
      "time_published": "20251016T124700",
      "authors": [
        "PR Newswire"
      ],
      "summary": "Citius Oncology has signed an exclusive commercialization agreement with EVERSANA to support the planned Q4 2025 launch of LYMPHIR\u2122, an FDA-approved targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). EVERSANA will provide integrated pre- and post-launch services including medical information, pharmacovigilance, and revenue cycle management. This partnership aims to enhance Citius Oncology's commercial capabilities and ensure timely market access for LYMPHIR\u2122.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.729514"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.510610"
        }
      ],
      "overall_sentiment_score": 0.04809,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "0.329025",
          "ticker_sentiment_score": "0.008169",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "When Will Citius Oncology, Inc. (NASDAQ:CTOR) Turn A Profit?",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctor/citius-oncology/news/when-will-citius-oncology-inc-nasdaqctor-turn-a-profit",
      "time_published": "20250927T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Citius Oncology, Inc. (NASDAQ:CTOR) is projected by analysts to turn a profit by 2027, with a final loss expected in 2026. To reach this breakeven point in approximately two years, the company would need to grow at an optimistic average annual rate of 65%. Despite broadening losses, Citius Oncology maintains a prudent capital structure with low debt, primarily funding operations through equity.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924289"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.818194"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.720953"
        }
      ],
      "overall_sentiment_score": 0.279273,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.258349",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14%",
      "url": "https://finance.yahoo.com/news/citius-oncology-inc-nasdaq-ctor-112905459.html",
      "time_published": "20250926T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Public companies, specifically Citius Pharmaceuticals, Inc., hold a dominant 79% ownership stake in Citius Oncology, Inc., giving them significant influence over management decisions. Individual investors hold 14% while insiders collectively own about US$9.4m. The article highlights the importance of understanding ownership structures and notes the absence of institutional investors.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923808"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.724056"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.628779"
        }
      ],
      "overall_sentiment_score": 0.133211,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.103719",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement",
      "url": "https://www.prnewswire.com/news-releases/citius-oncology-announces-pricing-of-9-0-million-registered-direct-offering-and-concurrent-private-placement-302550263.html",
      "time_published": "20250909T083000",
      "authors": [],
      "summary": "Citius Oncology, Inc. announced the pricing of a registered direct offering and concurrent private placement expected to generate approximately $9.0 million. The company will sell 5,142,858 shares of common stock and issue unregistered warrants to a single institutional investor, with the offering expected to close around September 10, 2025. This financing aims to support the company's development and commercialization of targeted oncology therapies, particularly its recently FDA-approved LYMPHIR.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.938834"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.848433"
        }
      ],
      "overall_sentiment_score": 0.192698,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.208867",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology Anticipates Commercial Launch of LYMPHIR\u2122 in 2025",
      "url": "https://www.prnewswire.com/news-releases/citius-oncology-anticipates-commercial-launch-of-lymphir-in-2025-302482826.html",
      "time_published": "20250617T080800",
      "authors": [],
      "summary": "Citius Oncology is on track for the commercial launch of its FDA-approved immunotherapy, LYMPHIR\u2122, in the second half of 2025, for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company has completed commercial-scale manufacturing, secured supply chain and distribution partners, and engaged with Key Opinion Leaders and patient organizations. LYMPHIR's inclusion in NCCN guidelines and J-code assignment are expected to facilitate reimbursement as Citius Oncology transitions into a commercial-stage company.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943744"
        },
        {
          "topic": "finance",
          "relevance_score": "0.712436"
        }
      ],
      "overall_sentiment_score": 0.469591,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.453794",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives",
      "url": "https://www.prnewswire.com/news-releases/citius-oncology-engages-jefferies-as-exclusive-financial-advisor-to-explore-strategic-alternatives-302342405.html",
      "time_published": "20250106T075000",
      "authors": [],
      "summary": "Citius Oncology, Inc. has engaged Jefferies LLC as its exclusive financial advisor to explore strategic alternatives aimed at maximizing shareholder value, including potential partnerships, mergers, and licensing agreements. This decision comes as the company prepares to launch LYMPHIR\u2122, its recently FDA-approved cancer therapy for relapsed or refractory cutaneous T-cell lymphoma, with an initial market estimated to exceed $400 million. Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, emphasizes its commitment to delivering value to shareholders and making an impact in oncology.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.914625"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.935643"
        }
      ],
      "overall_sentiment_score": 0.241638,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.426169",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MCK",
          "relevance_score": "0.643655",
          "ticker_sentiment_score": "0.144612",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CTOR Stock Price and Chart \u2014 NASDAQ:CTOR",
      "url": "https://www.tradingview.com/symbols/NASDAQ-CTOR/",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "This article provides a comprehensive overview of Citius Oncology, Inc. (CTOR) stock performance, key financial statistics, and analyst ratings. It includes current and historical price data, market capitalization, earnings information, and future forecasts, along with details about the company's pharmaceutical focus.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.905203"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.940689"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.900884"
        }
      ],
      "overall_sentiment_score": 0.146427,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.143801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital",
      "url": "https://finance.yahoo.com/news/citius-pharmaceuticals-upgraded-buy-hold-121025304.html",
      "time_published": "20241231T121025",
      "authors": [
        "TipRanks"
      ],
      "summary": "D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold, setting a $9 price target, citing the potential of its 90%-owned subsidiary, Citius Oncology (CTOR). The upgrade is based on the anticipated commercialization of Lymphir, an immunotherapy for T-cell lymphoma, which the firm expects to be a significant value driver for Citius Pharmaceuticals. The analyst also highlights Lymphir's progress in development and approval.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934628"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.805523"
        }
      ],
      "overall_sentiment_score": 0.419298,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.416877",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA\u00ae) and LYMPHIR\u2122 in Cancer Patients with Recurrent Solid Tumors",
      "url": "https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-preliminary-results-of-an-investigator-initiated-phase-i-clinical-trial-of-pembrolizumab-keytruda-and-lymphir-in-cancer-patients-with-recurrent-solid-tu-302300516.html",
      "time_published": "20241111T084500",
      "authors": [],
      "summary": "Citius Pharmaceuticals and Citius Oncology announced promising preliminary results from a Phase I clinical trial combining pembrolizumab (KEYTRUDA\u00ae) and LYMPHIR\u2122 for recurrent solid tumors, particularly gynecological cancers. The chemotherapy-free regimen showed a 27% objective response rate and a 33% clinical benefit rate with a median progression-free survival of 57 weeks, and was well-tolerated with minimal immune-related adverse events. These findings suggest LYMPHIR can enhance checkpoint inhibitor efficacy by depleting T-regulatory cells, supporting advancement to a Phase II study.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.40435,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.498004",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MRK",
          "relevance_score": "0.633279",
          "ticker_sentiment_score": "0.309190",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.",
      "url": "https://www.prnewswire.com/news-releases/citius-pharmaceuticals-completes-merger-of-subsidiary-with-tenx-keane-to-form-citius-oncology-inc-302220303.html",
      "time_published": "20240812T162200",
      "authors": [],
      "summary": "Citius Pharmaceuticals announced the completion of the merger of its oncology subsidiary with TenX Keane Acquisition, forming Citius Oncology, Inc. Citius Pharma will hold approximately 90% of the new public company, which is expected to begin trading on Nasdaq under the ticker \"CTOR\" on August 13, 2024. This move aims to provide greater financial and strategic flexibility, particularly following the FDA approval of LYMPHIR\u2122 for cutaneous T-cell lymphoma.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.922339"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.836142"
        },
        {
          "topic": "finance",
          "relevance_score": "0.642562"
        }
      ],
      "overall_sentiment_score": 0.889258,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CTOR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.898449",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}